Hsbc Holdings PLC Increases Stake in Charles River Laboratories International, Inc. $CRL

Hsbc Holdings PLC raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,682 shares of the medical research company’s stock after buying an additional 7,598 shares during the period. Hsbc Holdings PLC’s holdings in Charles River Laboratories International were worth $11,977,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Jones Financial Companies Lllp raised its stake in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after acquiring an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new position in Charles River Laboratories International during the 1st quarter worth $418,000. American Century Companies Inc. increased its holdings in Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the period. Brown Advisory Inc. raised its position in Charles River Laboratories International by 5.1% in the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock valued at $354,000 after purchasing an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System raised its position in Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock valued at $12,837,000 after purchasing an additional 3,198 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In related news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $218.44 on Thursday. The stock has a 50 day moving average price of $195.88 and a 200 day moving average price of $187.04. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $10.52 billion, a price-to-earnings ratio of -58.09, a price-to-earnings-growth ratio of 2.44 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $237.86.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the company earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Research analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent research reports. Mizuho upped their target price on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.